Eisen Maigi, Hartmane Ilona, Kingo Külli, Mikazans Ingmars, Toomson Tiina, Toomela Karin, Valiukeviciene Skaidra
Center of Dermatology and Venereology, The North Estonia Medical Centre, 13419 Tallinn, Estonia.
Department of Dermatology and Venereology, Faculty of Medicine, Riga Stradins University, LV-1010 Riga, Latvia.
Medicina (Kaunas). 2025 Feb 25;61(3):397. doi: 10.3390/medicina61030397.
: Data on disease control, treatment, and quality of life (QoL) in patients with psoriasis from Baltic countries are lacking. In this study, we aimed to assess the disease control, treatment, and QoL of patients with psoriasis in countries from Central and Eastern Europe, and we report data for the Baltic countries. : In a cross-sectional, international study (CRYSTAL), we retrospectively assessed the real-world disease severity and QoL in adult patients (18-75 years) from Estonia, Latvia, and Lithuania with moderate-to-severe psoriasis receiving continuous systemic treatment ≥ 24 weeks. Analyses included 50 patients from each country and were descriptive. : The median disease duration was 15.2-19.9 years across the countries. Most patients (78.0% in Estonia, 100% in Latvia, and 68.0% in Lithuania) were receiving monotherapy with biological agents, mainly TNF inhibitors. An absolute PASI score ≤ 3 was achieved by 82.0%, 70.0%, and 64.0% of patients in the overall study population and 89.7%, 70.0%, and 61.8% of patients receiving biologic monotherapy in Estonia, Latvia, and Lithuania, respectively. Across the countries, impairments in QoL as expressed by a Dermatology Life Quality Index score > 5 were reported by 14.0-34.0% of patients, while 88.0-96.0% of patients were satisfied with their treatment. : Although most patients showed low absolute PASI scores and satisfaction with their evolution after ≥24 weeks of systemic treatment, they still reported an impact on QoL. This finding underlines that further optimization of systemic treatment strategies is needed to improve outcomes in moderate-to-severe psoriasis in Baltic countries.
波罗的海国家缺乏有关银屑病患者疾病控制、治疗及生活质量（QoL）的数据。在本研究中，我们旨在评估中东欧国家银屑病患者的疾病控制、治疗及生活质量，并报告波罗的海国家的数据。
在一项横断面国际研究（CRYSTAL）中，我们回顾性评估了来自爱沙尼亚、拉脱维亚和立陶宛的18至75岁中重度银屑病成年患者在接受持续系统治疗≥24周后的真实世界疾病严重程度和生活质量。分析纳入了每个国家的50名患者，且为描述性分析。
各国的疾病中位病程为15.2至19.9年。大多数患者（爱沙尼亚为78.0%，拉脱维亚为100%，立陶宛为68.0%）接受生物制剂单药治疗，主要是肿瘤坏死因子抑制剂。在整个研究人群中，分别有82.0%、70.0%和64.0%的患者达到绝对银屑病面积和严重程度指数（PASI）评分≤3；在爱沙尼亚、拉脱维亚和立陶宛接受生物制剂单药治疗的患者中，这一比例分别为89.7%、70.0%和61.8%。在所有国家中，皮肤病生活质量指数评分>5所表明的生活质量受损情况在14.0%至34.0%的患者中存在，而88.0%至96.0%的患者对其治疗感到满意。
尽管大多数患者在系统治疗≥24周后显示出较低的绝对PASI评分并对病情进展感到满意，但他们仍报告生活质量受到影响。这一发现强调，需要进一步优化系统治疗策略以改善波罗的海国家中重度银屑病的治疗效果。
